Adisord, 200 mg capsules 20 pcs

Nifuroxazide is a nitrofuran derivative with antimicrobial effect against Gram-positive Staphylococcus spp. and some Gram-negative microorganisms: Yersinia spp., Escherichia spp., Citrobacter spp., Enterobacter spp., Salmonella spp.

Nifuroxazide has no antimicrobial activity against Proteus vulgaris, Klebsiellaspp., Proteus mirabilis and Pseudomonas aeruginosa. Supposedly blocks the activity of dehydrogenases and inhibits respiratory chains, tricarboxylic acid cycle and a number of other biochemical processes in the microbial cell. It does not disturb the balance of intestinal microflora.

In acute bacterial diarrhea it restores intestinal eubiosis. In case of infection with enterotropic viruses it prevents the development of bacterial superinfection.

Indications

Diarrhea of ​​bacterial origin without signs of helminthic infestation.

Pharmacological effect

Nifuroxazide is a nitrofuran derivative that has an antimicrobial effect against gram-positive Staphylococcus spp., and some gram-negative microorganisms: Yersinia spp., Escherichia spp., Citrobacter spp., Enterobacter spp., Salmonella spp.

Nifuroxazide does not have an antimicrobial effect against Proteus vulgaris, Klebsiellaspp., Proteus mirabilis and Pseudomonas aeruginosa. Presumably blocks the activity of dehydrogenases and inhibits the respiratory chain, the tricarboxylic acid cycle and a number of other biochemical processes in the microbial cell. Does not disturb the balance of intestinal microflora.

In acute bacterial diarrhea, it restores intestinal eubiosis. When infected with enterotropic viruses, it prevents the development of bacterial superinfection.

Special instructions

Rehydration should be carried out if necessary. The volume of fluid administered and the method of its administration (parenterally, intravenously) should correspond to the severity of diarrhea, age and clinical condition
the patient’s condition.

In case of bacterial diarrhea with signs of systemic damage (deterioration of general condition, increased body temperature, symptoms of intoxication or infection), you should consult a doctor about the use of systemic antimicrobial drugs.
During therapy with nifuroxazide, alcohol consumption is prohibited.

If symptoms of an allergic reaction appear (including shortness of breath, skin rash, itching), you should stop taking the drug.
Impact on the ability to drive vehicles and machinery

The drug Adisord® does not affect the ability to drive vehicles or engage in other potentially hazardous activities.

Active ingredient

Nifuroxazide

Composition

Capsules 200 mg.

1 capsule contains:

active substance:

nifuroxazide 200 mg;

excipients:

calcium hydrogen phosphate dihydrate 50 mg,

pregelatinized corn starch 66 mg,

mannitol 40 mg,

magnesium stearate 2 mg,

talc 2 mg;

hard gelatin capsule No. 0: body – titanium dioxide 0.7867 mg, gelatin 57.6681 mg, quinoline yellow dye 0.5426 mg, sunset yellow dye 0.0026 mg.

cap – titanium dioxide 0.4933 mg, gelatin 36.1648 mg, quinoline yellow dye 0.3403 mg, sunset yellow dye 0.0016 mg.

Contraindications

hypersensitivity to nifuroxazide, nitrofuran derivatives or any excipients of the drug
children under 3 years of age.

Side Effects

Immune system disorders: allergic reactions (skin rash, urticaria, Quincke’s edema, shortness of breath, anaphylactic shock). General disorders and disorders at the injection site: abdominal pain, nausea, increased diarrhea, granulocytopenia.

If any of the side effects indicated in the instructions get worse, or you notice any other side effects not listed in the instructions, tell your doctor.

Interaction

When taken simultaneously with ethanol, a disulfiram-like reaction may develop (abdominal pain, nausea, vomiting, headache, tachycardia, blurred vision, weakness, convulsions).

Concomitant use with drugs that inhibit the function of the central nervous system is not recommended.

Overdose

Overdose symptoms are not described.

In case of overdose, gastric lavage and symptomatic treatment are recommended.

Specifications

Dosage 200 mg

1 capsule contains:

active substance:

nifuroxazide 200 mg;

excipients:

calcium hydrogen phosphate dihydrate 50 mg,

pregelatinized corn starch 66 mg,

mannitol 40 mg,

magnesium stearate 2 mg,

talc 2 mg;

hard gelatin capsule No. 0:
body – titanium dioxide 0.7867 mg, gelatin 57.6681 mg, dye
quinoline yellow 0.5426 mg, sunset yellow dye 0.0026 mg.

cap – titanium dioxide 0.4933 mg, gelatin 36.1648 mg, dye
quinoline yellow 0.3403 mg, sunset yellow dye 0.0016 mg.

Storage conditions

In a dry place, protected from light, at a temperature not exceeding 25 ° C.

Shelf life

2 years.

Manufacturer

Kanonpharma production CJSC, Russia